 NEW HAVEN, Conn., May 6, 2021 PRNewswire -- Trevi Therapeutics, Inc. NASDAQ: TRVI, a clinical-stage biopharmaceutical company focused on the development and commercialization of an investigational therapy HaduvioTM nalbuphine ER to treat serious neurologically mediated conditions, today announced that management will host a conference call and live audio webcast on Thursday, May 13 at 4:30 p.m. 